On June 11, 2024, the Phase II study results of Garsorasib (D-1553) for KRAS G12C-mutant non-small cell lung cancer (NSCLC) were published in The Lancet Respiratory Medicine, one of the world’s most prestigious medical journals (Impact Factor: 76.2). This study, conducted in China, highlighted the promising efficacy and safety profile of Garsorasib, marking it as…